Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01581879 · ClinicalTrials.gov registry record · Phase 1

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions

A Phase 1 study of Healthy, sponsored by Dr. Reddy's Laboratories Limited.

Completed
Registry status
Phase 1
Development phase
38
Enrollment target
1
Study location

NCT01581879 is a Phase 1 study of Healthy that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 38 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01581879, a Phase 1 study of Healthy, has completed, sponsored by Dr. Reddy's Laboratories Limited.

COMPLETED
Registry status
Phase 1
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to compare the rate and extent of absorption of ziprasidone 20 mg capsules versus Geodon 20 mg capsules under fed conditions.

Conditions Studied

Interventions

  • DRUG Ziprasidone Hydrochloride

Study Locations (1)

Florida

  • SFBC Ft. Myers, Inc. - Fort Myers

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2004-11
Est. Completion 2005-01
Phase Phase 1

Sponsor

Dr. Reddy's Laboratories Limited

52 total trials

What the Registry Record Tells You About NCT01581879

The ClinicalTrials.gov registry entry for NCT01581879 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Dr. Reddy's Laboratories Limited, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Ziprasidone Hydrochloride is the first listed.

NCT01581879 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01581879 about?

NCT01581879 is a clinical study titled "Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions". The objective of this study is to compare the rate and extent of absorption of ziprasidone 20 mg capsules versus Geodon 20 mg capsules under fed conditions.

What is the current status of trial NCT01581879?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2004-11. Estimated completion is 2005-01.

What conditions does trial NCT01581879 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01581879?

The interventions under investigation include: Ziprasidone Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT01581879?

This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01581879 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.